Index Overhaul and Inflation Jolt: The MSCI World ETF Prepares for Its Most Eventful Week

MSCI World ETF (up 30% in 12 months) faces May rebalancing, overbought RSI 94.6, US inflation at 3.8%, and Powell's term ending, testing the tech-heavy rally.

The MSCI World ETF is entering a stretch that will test both its structural resilience and the staying power of its tech-heavy rally. With an index rebalancing set for the end of May, a hotter-than-expected US inflation reading, and the clock ticking on Jerome Powell’s tenure as Fed chair, the fund finds itself squeezed from multiple directions.

The index provider MSCI released its May review results on 12 May, and the changes will take effect at the close of trading on 29 May. At the broader ACWI level, 49 stocks will be added and 101 removed. For the developed-market MSCI World, the largest new constituents by market capitalisation are Medline A, MasTec and TechnipFMC — names that tilt toward healthcare, infrastructure and energy services. The rebalancing will carry extra weight this time because MSCI is simultaneously rolling out a more granular free-float methodology from 1 June, distinguishing more precisely between high, medium and low free-float tiers. A physically replicating ETF must buy and sell shares to mirror those changes, and because the previous adjustment was deliberately modest, trading volumes this month could be conspicuously higher.

The fund’s underlying momentum remains firmly in the grip of Big Tech. Nvidia commands a 5.57% weight, Apple 4.58% and Microsoft 3.31%. Samsung Electronics, also in the benchmark, delivered a standout quarter with operating profit of 57.2 trillion won — a multiple of the year-ago figure — and its market capitalisation breached $1 trillion for the first time, helped by speculation about chip partnerships with Apple and Intel. The ETF itself has returned 8.27% year-to-date and an impressive 29.68% over the past twelve months, with assets under management climbing to roughly $8.02 billion. Yet the technical picture is flashing amber: the relative strength index stands at 94.6, well into overbought territory.

The macro backdrop is turning less forgiving. US consumer prices rose 0.6% in April, pushing the annual rate to 3.8% — the highest since May 2023. Core inflation edged up 0.4% month-on-month, while energy costs surged 17.9% over the past year. The Federal Reserve held its benchmark rate at 3.50–3.75%, but the vote was unusually split at 8 to 4, and futures markets have now priced out any rate cut for 2026. Higher yields directly pressure the valuation models of growth stocks, precisely the names that dominate the ETF’s portfolio.

Compounding the uncertainty, Jerome Powell’s term as Fed chair concludes on 15 May. Although he will remain on the Board of Governors, a change at the top can shift the central bank’s tone, and markets are on alert for any signal.

Additional headwinds are gathering in the healthcare sector, where the US plans to phase in tariffs on imported patented drugs from the end of July. Products from the EU, Japan, South Korea and Switzerland would face a 15% levy, British goods 10%, and companies without US price agreements could see tariffs as high as 100%. FactSet has already lowered earnings estimates for the sector.

On fees, the pressure is relentless. BlackRock’s iShares MSCI World ETF charges a total expense ratio of 0.24% and maintains a tracking difference of just 0.02%, but rivals are undercutting: Invesco offers a competing product at 0.05%, and URTH sits at 0.24%. Despite the competition, the fund has attracted net inflows of $770 million so far this year.

The immediate line in the sand is 29 May, when the new index weights are implemented. After that, the market’s focus will shift to how long elevated interest rates can coexist with richly valued tech stocks — and whether the index overhaul adds an extra layer of volatility to the process.